Visual remediation of contrast processing impairments in schizophrenia: A preliminary clinical trial.

Clinical trial Cognitive remediation Contrast sensitivity Perceptual organization Schizophrenia Visual remediation

Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
30 Oct 2024
Historique:
received: 30 06 2024
revised: 25 09 2024
accepted: 19 10 2024
medline: 1 11 2024
pubmed: 1 11 2024
entrez: 31 10 2024
Statut: aheadofprint

Résumé

Schizophrenia (SZ) is associated with visual processing impairments, which are related to higher-level functional impairments. This study investigated the impact of a novel visual remediation intervention (VisR) targeting low- and mid-level visual processing impairments in SZ. We hypothesized that VisR would lead to greater improvements in contrast processing when compared to an active control condition and explored potential treatment-related changes in symptom severity. SZ participants (N = 47) were randomized into one of four groups: an active control group (cognitive training; AC); Contrast Sensitivity Training + AC (CST + AC); Contour Integration Training + AC (CIT + AC); and CST + CIT. Participants completed 20-40 training sessions. Clinical symptom severity was assessed using the Positive and Negative Syndrome Scale and contrast processing was assessed using steady-state visual evoked potentials to increasing levels of contrast of isolated-check pattern stimuli. A significant Group × Timepoint × Contrast interaction indicated superiority of CST + CIT over AC for improving contrast processing. Furthermore, a large, significant Group × Timepoint interaction indicated that CST + CIT was associated with a greater reduction in positive symptoms compared to AC. In addition, lower severity of positive symptoms at baseline was associated with a greater improvement in contrast processing over the course of treatment. This initial evaluation of VisR demonstrated that it is well tolerated and may produce greater improvements in contrast processing and positive symptoms compared to an intervention targeting only high-level cognitive functions.

Identifiants

pubmed: 39481234
pii: S0920-9964(24)00453-5
doi: 10.1016/j.schres.2024.10.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

396-405

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest I have nothing to declare.

Auteurs

Zachary Bergson (Z)

Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA. Electronic address: zbergson@mail.yu.edu.

Anthony O Ahmed (AO)

Department of Psychiatry, Weill Cornell Medicine, White Plains, NY, USA. Electronic address: aoa9001@med.cornell.edu.

Jewel Bell (J)

Department of Psychiatry, Weill Cornell Medicine, White Plains, NY, USA. Electronic address: jeb4018@med.cornell.edu.

Pamela D Butler (PD)

Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA. Electronic address: Pam.Butler@nki.rfmh.org.

James Gordon (J)

Department of Psychology, Hunter College, NY, New York, USA. Electronic address: jgordon@hunter.cuny.edu.

Aaron R Seitz (AR)

Department of Psychology, Northeastern University, Boston, MA, USA. Electronic address: a.seitz@northeastern.edu.

Steven M Silverstein (SM)

Departments of Psychiatry, Neuroscience, and Ophthalmology, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: Steven_Silverstein@urmc.rochester.edu.

Judy L Thompson (JL)

Departments of Psychiatry and Neuroscience, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: Judy_Thompson@urmc.rochester.edu.

Vance Zemon (V)

Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA.

Classifications MeSH